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Abstract This study aimed to determine the predictors of
increased risk of a second demyelinating event within the
first year of an initial demyelinating event (IDE) suggestive
of early multiple sclerosis (MS). Patients with MS or clini-
cally isolated syndrome (CIS) seen at the UCSF MS Center
within one year of the IDE were studied. Univariate and
multivariate Cox models were used to analyze predictors of
having a second event within 1 year of the IDE. Of 330
patients with MS/CIS, 111 had a second event within 1 year.
Non-white race/ethnicity (HR = 2.39, 95% CI [1.58, 3.60],
p \ 0.0001) and younger age (HR for each 10-year decrease
in age = 1.51, 95% CI [1.28, 1.80], p \ 0.0001) were
strongly associated with an increased risk of having a second
event within one year of onset. Having a lower number of
functional systems affected by the IDE was also associated
with an increased risk of early second event (HR for every
one less FS involved = 1.31, 95% CI [1.06, 1.61],
p = 0.011). These results were similar after adjusting for
treatment of the IDE with steroids and disease-modifying
therapy. Non-white race/ethnicity, younger age, and a lower
number of FS affected by the IDE are associated with a
substantially increased hazard ratio for a second demyelin-
ating event within 1 year. Since early relapse is predictive of
worse long-term outcome, identifying and treating such
patients after the IDE may be of benefit to them.
Keywords Multiple sclerosis  Epidemiology 
Clinical studies  Demyelinating diseases
Introduction
With the advent of disease-modifying therapies (DMTs) for
relapsing remitting multiple sclerosis (RRMS), the scien-
tific community has been under increasing pressure to
improve the sensitivity of the diagnostic criteria for RRMS
early in the disease course [1]. Furthermore, many experts
urge the initiation of DMTs after the initial demyelinating
event (IDE) in patients at high risk for subsequent attacks
rather than waiting for dissemination in time based on MRI
or clinical outcomes [2]. In practice, however, many
patients do not start on DMTs after the first clinical event,
in part due to delayed evaluation by a neurologist, uncer-
tainty surrounding the diagnosis, or the patient’s resistance
to beginning injectable treatment.
One common clinical problem in discussing the ben-
efits of early treatment with patients is that it is difficult
to predict which individuals are most at risk for relapse
in the immediate future. Studies have identified prog-
nostic factors for disability in the long-term (i.e. 10 or
20 years after disease onset) [3], predictors of relapse rate
in patients with established MS [4–6], or magnetic res-
onance imaging (MRI) or other paraclinical features that
increase the risk of conversion to MS [7–11], but few
have evaluated clinical risk factors for early relapse in
MS [12, 13].
We sought to explore potential predictors of increased
risk of a second demyelinating event within 1 year of MS
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onset with the goal of confirming and extending findings of
our previous report in a larger cohort of patients [13]. Since
evidence suggests that early relapse is predictive of worse
long-term outcomes [14–17], identifying patients most at
risk for such may help clinicians to advise them about
DMT.
Methods
This project was approved by the UCSF Committee on
Human Research and was performed in accordance with
the Declaration of Helsinki. Clinical and demographic
information for all patients seen at the UCSF MS Center is
entered into a Microsoft SQL server database (retrospec-
tively when patients are first seen in clinic and then
prospectively as patients return for follow-up visits). Reg-
ular follow-up visits typically occur every 6 months, and
unscheduled visits occur if a patient has an exacerbation.
We queried the database for all CIS and RRMS patients
seen within the first year of disease onset between January
2000 and June 2007 [13, 18].
Patients were split into two groups to analyze the effects
of race/ethnicity: white, non-Hispanics (referred to as
whites in the rest of the manuscript) and non-whites (all
others). Demyelinating events were defined as new or
recurring neurologic symptoms referable to the central
nervous system (CNS) lasting for at least 48 h after a
remission of 30 days or more since the previous event.
Pseudo-exacerbations were excluded. Based on clinical
history and examination, each patient’s relapses were
coded as occurring in the spinal cord, brainstem/cerebel-
lum, optic nerve, or cerebrum. If the event involved at least
two of these locations, it was considered polyregional. The
number of functional systems (FS; e.g. sensory, motor,
bladder/bowel) affected by the IDE was also calculated
(possible range 1–7) [19]. Disease-modifying therapy
(DMT) status was recorded. A patient was considered as
being on DMT after he/she had at least 90 days of con-
tinuous treatment. This time period was used because it is
an accepted length of time in which standard DMTs reach
therapeutic effectiveness [20, 21].
The severity of and recovery from the first event was
determined by trained individuals as previously described
[8, 13]. Briefly, mild IDE severity was defined as FS scores
of 0–1 in 1–3 FS, but no higher than 1 or visual acuity
(VA) better than or equal to 20/40, EDSS score range of
0–1.5 inclusive; moderate severity was defined as a score
of at least 2, but not higher than 2 in one or two FS or four
or more scores of 1 or VA of 20/50–20/190, EDSS score
of 2.0–2.5 inclusive; severe was assigned for relapses
exceeding prior criteria. IDE recovery was scored using the
lowest EDSS and FS scores reported between two and
12 months after the attack. It was considered complete (no
residual complaint, normal follow-up examination, all FS
scores = 0, follow-up EDSS score = 0), fair (residual
subjective complaint that does not impair activity, or at
least one FS score of 1 at most or VA better or equal to
20/40, follow-up EDSS score = 1.0–1.5), or poor (residual
deficits exceeding prior criteria).
Increased risk of early second event was analyzed using
the Cox proportional hazards model. Hazard ratios (HRs)
were generated with 95% confidence intervals (CIs) and p
values. For comparability with a previous study [13], we
performed the analyses including only events that occurred
within 1 year of disease onset. Potential predictors inclu-
ded sex, race/ethnicity, age at onset, severity and recovery
of the IDE, event location, monoregional versus polyre-
gional presentation, steroid treatment for the first event,
DMT status, and initial brain MRI scan results (normal vs.
at least one T2-weighted hyperintense lesion), also chosen
for comparability with the previous study [13]. Since DMT
status changes with time, it was treated as a time-dependent
covariate. Interactions between age, race, and DMT with
subgroup (included in previous analysis vs. not) were
evaluated. Tests of the proportional hazards assumption did
not show strong evidence of any violations. For predictors
that seemed to be important, we created Kaplan–Meier
curves after generating a dichotomous predictor (for ease
of presentation), when the original predictor was ordinal or
continuous. We also performed sensitivity analyses that
excluded the subjects who had been included in the pre-
vious cohort.
Results
Patient and event characteristics
We identified 330 patients (224 females) seen at the UCSF
MS Center within a year of initial MS symptoms; mean
follow-up was 759 ± 575 days (median 633 days, range
23–2,692 days). The mean age at IDE onset was
34 ± 12 years. Two hundred and sixty-seven (80.9%)
patients were Caucasian; the remainder included 21 (6%)
African Americans, 15 (5%) Asians, 14 (4%) Hispanic or
Latinos, and 13 (4%) others (unknown). At onset, 301
(93%) of the 323 patients who had available brain imaging
had an abnormal brain MRI.
Most IDEs (85%) were monoregional; event locations,
severity, and recovery are presented in Table 1. Within the
first year, 111 patients (34%) experienced a second event.
Of the 219 patients who did not have a second event within
a year, there was at least 1 year of follow-up for 134
(61%). The mean follow-up for the remaining 85 patients
was 174 ± 94 days.
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One hundred and fifty-three (46%) patients received
high dose steroid therapy for the IDE. DMT was initiated
in 54% of patients (n = 177) during the entire follow-up
period (Avonex 29%, Rebif 10%, Copaxone 8%, Betas-
eron 6%, other 1%); 105 began therapy within 1 year of
the IDE. However, only nine patients who had a second
event within a year of the first had at least 90 days of
DMT before the second event (i.e. had an on-therapy
relapse).
Factors associated with early risk of second event
In the univariate Cox models, non-white race (HR = 2.39,
95% CI [1.58, 3.60], p \ 0.0001) and younger age (HR for
each 10-year decrease in age = 1.51, 95% CI [1.28, 1.80],
p \ 0.0001) were associated with a substantial increase in
risk of a second event within the year after the IDE
(Fig. 1). Fewer FS involved in the IDE predicted an
increased risk of early second event (HR for each one less
FS = 1.31, 95% CI [1.06, 1.61], p = 0.011) (Fig. 1). Fair
versus complete IDE recovery conferred a reduction in the
HR for a second event (HR = 0.76, 95% CI [0.50, 1.14],
p = 0.180); poor versus complete recovery seemed to be
associated with an even lower risk (HR = 0.57, 95% CI
0.31, 1.04], p = 0.069, although there was substantial
overlap of the CIs. DMT status did not appear to sub-
stantially alter the HR for a second event within a year
(HR = 0.98, 95% CI [0.48, 2.01], p = 0.96), but there was
wide uncertainty around this estimate. First event severity,
sex, location of onset, abnormal versus normal brain MRI,
polyregional onset, and steroid treatment for the IDE did
not appear to strongly influence the hazard of an early
second event.
Non-white race, younger age, and a lower number of FS
affected by the IDE remained strong and independent
predictors of increased risk of a second event within 1 year
Table 1 Characteristics of the initial demyelinating event
Event characteristic n = 330
Location, n (%)a
Spinal cord 175 (53)
Brainstem/cerebellum 110 (33)
Optic nerve 86 (26)
Cerebrum 10 (3)
Severity, n (%)
Mild 134 (41)
Moderate 139 (42)
Severe 57 (17)
Recovery, n (%)b
Complete 150 (46)
Fair 118 (37)
Poor 54 (17)
a Total does not add up to 100% since 48 patients (15%) had multiple
sites affected
b Incomplete data for some individuals
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in the multivariate model that included these predictors as
well as steroid treatment for the IDE and DMT (Table 2).
We then performed a sensitivity analysis, excluding the
176 patients who had been included in a prior analysis [13].
Only the 154 seen after January 1, 2005 were included in
this evaluation. The univariate analyses demonstrate that
non-white race (HR = 2.11, 95% CI [1.10, 4.03],
p = 0.025) and younger age (HR for 10-year decrease in
age = 1.69, 95% CI [1.33, 2.14], p \ 0.0001) were still
very strong predictors of increased risk of an early second
event. That the p value for non-white race is weaker
reflects the decreased sample size, which also predicts
widened CIs. While the number of FS was no longer as
strong a predictor, the trend was in a similar direction (HR
for every one less FS involved = 1.16, 95% CI [0.90,
1.51], p = 0.25). Poor versus complete recovery from the
IDE was still predictive of a lower risk for another event
within a year (HR = 0.48, 95% CI [0.20, 1.17], p = 0.11).
Tests for interaction of age or race/ethnicity with the
two subgroups did not produce strong evidence for any
meaningful interactions. On the other hand, the test for
interaction of DMT and the two cohorts was statistically
significant (p = 0.019). In the new cohort of patients,
DMT was associated with an increased HR for second
event within 1 year (HR = 2.65, 95% CI [1.04, 6.76],
p = 0.041), whereas treatment with DMT in the previous
cohort was associated with a reduced risk of early second
event (HR = 0.41, 95% CI [0.13, 1.36], p = 0.14).
Discussion
The results reported herein support that non-white race/
ethnicity, younger age, and fewer FS associated with the
IDE substantially increase the risk for early relapse in
patients with CIS.
In previous studies, African American patients had more
rapid disease progression and/or were more likely to be
disabled than were Caucasians, suggesting that the long-
term course of MS may be more aggressive in the former
group, although specific predictors of such outcomes have
not been fully characterized [22–25]. Here, we included not
only African Americans, but also Asians, Hispanics or
Latinos, and patients of other racial/ethnic backgrounds as
‘‘not white’’ and demonstrated that non-white race/ethnic-
ity was associated with a higher risk of early second event,
independent of age or treatment status. This finding is
worrisome given that more activity in the first year of
disease onset has been associated with a poorer long-term
prognosis [14–17]. While some groups reported no differ-
ence in the percentage of African American versus white
patients who were treated with DMT [24, 25], it is
unknown if there are racial disparities in early initiation of
DMT, i.e. after the first demyelinating event. Certainly
other racial disparities in care have been documented in
MS [26]. More analyses are needed to determine if the non-
white individuals in our cohort experience a more aggres-
sive long-term disease course as well as to explore whether
there are systematic differences in treatment initiation.
That age is independently associated with early risk of
relapse is consistent with previous studies showing that
new gadolinium-enhancing lesions are less likely to
develop in older patients than in younger patients [27, 28].
The finding that older patients are less likely to have an
early second event after the IDE may relate to the same
factors that are responsible for the different onset ages,
whether genetic, biologic or both. Since younger patients
are more at risk for an early second event, the urgency of
starting therapy may be greater for a 25-year-old than a 55-
year-old individual, since the risk of early relapse is more
than four times higher for the former compared to the latter
patient. However, the ability of DMT to delay or prevent
the second event has not been studied specifically in high-
risk patients.
Having a higher number of FS involved or a poor or
moderate recovery from the IDE was associated with a
lower risk of early relapse. Perhaps patients who have more
concurrent or destructive demyelinating lesions are more
prone to temporarily suppress biologic disease processes
compared with those with less aggressive disease onset.
Alternatively, having more CNS territory involved in the
IDE or poor recovery may lead to masking of subtle sub-
sequent exacerbations, particularly if they occurred in
similar anatomic areas, such that the apparent relationship
between these predictors and time to next relapse is
explained by missed second events.
One perplexing finding of our study is that while for the
overall cohort, DMT did not appear to substantially change
the risk of an early second event, there was an interaction
between this predictor and when patients were first seen
(from January 2000 to January 2005 vs. January 2005 to
June 2007). In the more recent subgroup, DMT use was
associated with an increased HR for early second event.
These findings suggest that there are factors not captured in
Table 2 Results of the multivariate analysis for predictors of early
second event
Predictors Hazard
ratio
95% CI p value
Age (10-year decrease) 1.46 1.22, 1.74 \0.0001
Race/ethnicity (non-white vs. white) 2.06 1.34, 3.17 0.0010
Functional systems (per one less) 1.32 1.05, 1.67 0.020
Treatment of first attack with steroids 0.87 0.58, 1.32 0.51
Treatment with DMT 1.01 0.48, 2.16 0.97
DMT disease-modifying therapy
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this study that make the two groups different. Such
covariates could be due to differences in the patient pop-
ulation or due to changes in patterns of recommended
treatments. Perhaps practitioners in our group have become
more selective with respect to which patients should
receive early treatment by using clinical or paraclinical
data, such as brain MRI characteristics, that we did not
measure in this study. For example, if physicians tend to
initiate DMT in patients who have a higher burden of
disease on brain MRI, this would lead to a false impression
that the risk of relapse is higher on treatment when in fact;
such patients were already at a higher risk of early second
event [7, 9–11]. Further, only a small number of patients
are driving this finding since only nine patients (three in the
earlier and six in the later cohort), who had a second event
within a year of the IDE actually began DMT before it
occurred.
There are some limitations to our study. As our cohort
size was moderate, addressing this research question in a
larger cohort would be desirable, as it would provide more
accurate estimates and permit evaluations of more predic-
tors simultaneously in larger multivariate models. Also, it
would be valuable to evaluate a larger population of non-
white individuals, such that further determination of whe-
ther all, or only some, racial backgrounds predispose
patients to an increased risk of an early second event. Since
this is a clinical cohort, MRI scans were available for most
patients at the time of the initial clinical visit, but as
imaging protocols were not standardized nor were images
systematically stored in the radiology database at UCSF,
specific characteristics of the scans could not be analyzed
for this study. A confirmation study would also be helpful;
performing such a study in a large, multi-racial cohort with
standardized, longitudinal imaging and clinical follow-up
would be one good way to confirm our findings while
exploring MRI characteristics as covariate predictors of
early second event. Incorporating genetic studies, such as
HLA haplotype and gene expression, might also help to
increase our ability to understand which patients are at
greatest risk of early relapse and to elucidate the mecha-
nism by which factors that have already been identified,
such as non-white race and younger age, confer risk to
individuals who possess them.
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